222 related articles for article (PubMed ID: 10952579)
1. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.
Santangelo R; Paderu P; Delmas G; Chen ZW; Mannino R; Zarif L; Perlin DS
Antimicrob Agents Chemother; 2000 Sep; 44(9):2356-60. PubMed ID: 10952579
[TBL] [Abstract][Full Text] [Related]
2. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model.
Zarif L; Graybill JR; Perlin D; Najvar L; Bocanegra R; Mannino RJ
Antimicrob Agents Chemother; 2000 Jun; 44(6):1463-9. PubMed ID: 10817694
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B cochleates: a vehicle for oral delivery.
Perlin DS
Curr Opin Investig Drugs; 2004 Feb; 5(2):198-201. PubMed ID: 15043394
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis.
Delmas G; Park S; Chen ZW; Tan F; Kashiwazaki R; Zarif L; Perlin DS
Antimicrob Agents Chemother; 2002 Aug; 46(8):2704-7. PubMed ID: 12121962
[TBL] [Abstract][Full Text] [Related]
5. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
[TBL] [Abstract][Full Text] [Related]
6. In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2003 Sep; 52(3):412-8. PubMed ID: 12917237
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis.
Ibrahim F; Sivak O; Wasan EK; Bartlett K; Wasan KM
Lipids Health Dis; 2013 Oct; 12():158. PubMed ID: 24164705
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
9. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.
van Etten EW; ten Kate MT; Stearne LE; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 1995 Sep; 39(9):1954-8. PubMed ID: 8540697
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.
Mohamed HA; Radwan RR; Raafat AI; Ali AE
Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061
[TBL] [Abstract][Full Text] [Related]
11. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.
Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F
J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ
J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
Wasan KM; Conklin JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.
Khardori N; Nguyen H; Stephens LC; Kalvakuntla L; Rosenbaum B; Bodey GP
Antimicrob Agents Chemother; 1993 Apr; 37(4):729-36. PubMed ID: 8494367
[TBL] [Abstract][Full Text] [Related]
15. Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii.
Batista-Duharte A; Lastre M; Romeu B; Portuondo DL; Téllez-Martínez D; Manente FA; Pérez O; Carlos IZ
Int Immunopharmacol; 2016 Nov; 40():277-287. PubMed ID: 27639705
[TBL] [Abstract][Full Text] [Related]
16. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice.
Shadkchan Y; Segal E
J Antimicrob Chemother; 1999 Dec; 44(6):787-90. PubMed ID: 10590279
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis.
Desai JV; Urban A; Swaim DZ; Colton B; Kibathi LW; Ferrè EMN; Stratton P; Merideth MA; Hunsberger S; Matkovits T; Mannino R; Holland SM; Tramont E; Lionakis MS; Freeman AF
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0030822. PubMed ID: 35699443
[TBL] [Abstract][Full Text] [Related]
18. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
19. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
[TBL] [Abstract][Full Text] [Related]
20. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
